Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Joe Wesley who wrote (2388)	12/10/1998 8:50:00 AM
From: jopawa	Read Replies (2) \| Respond to of 4676

Thread, Let's hope this isn't a bit premature! Thursday December 10, 5:45 am Eastern Time Company Press Release SOURCE: Isis Pharmaceuticals Inc. Isis Pharmaceuticals' CEO to be Honored By Crohn's and Colitis Foundation of America NEW YORK, Dec. 10 /PRNewswire/ -- Isis Pharmaceuticals Inc. (Nasdaq: ISIP - news) announced that Chairman and CEO, Stanley T. Crooke, M.D., Ph.D., been chosen by the Greater New York Chapter of the Crohn's and Colitis Foundation of America (CCFA) to receive their 1998 ''Man of the Year Award,'' to be conferred this evening at their 31st Annual Dinner in New York. The Crohn's and Colitis Foundation of America is the only national non-profit health organization dedicated to finding the cause of, and medical cure for, these serious inflammatory bowel diseases (IBD). With over 70 chapters throughout the United States, their mission is to support basic and clinical scientific research in the area of these illnesses, provide educational programs for patients, medical professionals, and the general public and offer supportive services for patients and their families. The Man of the Year Award is given to an individual who demonstrates a desire for the betterment of patients afflicted with IBD. Dr. Crooke will be honored for his long and distinguished career in the medical and pharmaceutical industry and for Isis' work in the field of IBD drug development. ISIS 2302 is an antisense compound being tested against a variety of inflammatory conditions. ISIS 2302 demonstrated durable remission, steroid sparing, fistula healing and minimal side effects in a Phase II trial, and is currently in a pivotal quality trial as a treatment for Crohn's Disease. Mr. Mark Collar, President, Procter & Gamble Pharmaceuticals, Inc. will also receive the honor at this year's dinner in recognition of the company's work in supporting the CCFA over the years and its efforts in patient and professional education forums. ''I want to thank CCFA for the honor they have given to Isis in recognition of our goal to develop a potentially new treatment for Crohn's disease,'' said Dr. Crooke. ''Everyone at Isis and Boehringer Ingelheim, our development partner for ISIS 2302, shares CCFA's commitment to improving the health and quality of life for people with IBD. We are hopeful that antisense technology will represent a major medical advance for patients in need of safer and more effective treatments.'' Isis Pharmaceuticals, based in northern San Diego County, is engaged in the discovery and development of novel human therapeutic compounds. Isis has six compounds in human clinical trials: Vitravene™ (fomivirsen), to treat CMV-induced retinitis in AIDS patients, has been approved for marketing by the FDA and is currently undergoing regulatory review in Europe; ISIS 2302, an inhibitor of ICAM-1, is in a pivotal quality trial for Crohn's disease, Phase II clinical trials for renal transplant rejection, rheumatoid arthritis and ulcerative colitis, and is being explored as a topical administration for psoriasis and an aerosol administration for asthma; ISIS 3521 is in Phase II trials as a treatment for cancer; ISIS 5132 is in Phase II clinical trials as a treatment for cancer; ISIS 2503 is in Phase I trials as a treatment for cancer; and ISIS 13312 is in Phase I/II clinical trials for the treatment of CMV retinitis in AIDS patients. The company also has several additional compounds in preclinical development. Isis' broad medicinal chemistry and biology research programs support efforts in both antisense and small molecule drug discovery. This press release contains forward-looking statements concerning ISIS 2302, an antisense compound in development for Crohn's Disease. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. These and other risks concerning the clinical development of antisense compounds are described in additional detail in Isis' Annual Report on Form 10-K for the year ended December 31, 1997 which is on file with the U.S. Securities Exchange Commission, copies of which are available from the company. Vitravene™ is a trademark of Novartis AG.